Clinical Trials Logo

Solid Tumours clinical trials

View clinical trials related to Solid Tumours.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03150056 Terminated - Solid Tumours Clinical Trials

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Start date: July 18, 2017
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).

NCT ID: NCT02687386 Terminated - Solid Tumours Clinical Trials

A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

ECREST
Start date: February 8, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing, in children with recurrent/refractory solid or CNS tumours.

NCT ID: NCT02492477 Terminated - Solid Tumours Clinical Trials

TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients

Start date: January 2016
Phase: Phase 1
Study type: Interventional

The benefits and risks of flushing or not flushing the non-used PORT-A-CATH® in cancer patients and the time interval of eventual PORT-A-CATH® flushing are currently unknown. The manufacturers of PORT-A-CATH® recommend regular flushings every 4 weeks. In clinical practice, the intervals are usually at least three months. Regular flushing might lead to a decreased risk of PORT-A-CATH® thrombosis, but may also lead to an increased infection or thrombosis rate and patients discomfort. Therefore, this study investigates the safety of not flushing the PORT-A-CATH® for 6 or 12 months.

NCT ID: NCT01948297 Terminated - Solid Tumours Clinical Trials

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated. The main objective of Part A is to identify the dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose (MTD) based on the safety and tolerability of Debio1347 orally administered daily to these patients, in order to determine the recommended dose. The main objective of Part B is to evaluate the safety profile at the recommended dose, in a larger cohort of these patients.

NCT ID: NCT00695448 Terminated - Solid Tumours Clinical Trials

Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

Start date: June 24, 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.

NCT ID: NCT00497679 Terminated - Solid Tumours Clinical Trials

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.